Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02860572
Other study ID # 200/13/03/02/16
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 10, 2017
Est. completion date December 10, 2020

Study information

Verified date December 2020
Source Helsinki University Central Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background: After hypotension, oliguria (urine output less than 0.5 mL/kg/h) was the most common trigger to administer fluid bolus in a multinational practice survey in intensive care. The effect of fluid bolus on cardiovascular variables can be very short-lived among patients in shock suggesting that fluid boluses in the optimization phase are unlikely to improve patient-centered outcomes. Moreover, a growing body of evidence suggests a poor renal response to fluid bolus. Objective: To investigate, whether fluid bolus - as a standard of care - improves urine output in oliguric patients compared to a non-interventional follow-up approach without fluid bolus. Design: Investigator-initiated, open, randomized, controlled study Interventions: 1. Intervention group - follow-up without intervention 2. Control group - fluid bolus (500mL of balanced crystalloid over 30 minutes) Randomization: 1:1 stratified according to the site, presence of acute kidney injury, and sepsis Trial size: 130 patients randomized in 2 ICUs


Description:

Study hypothesis: The investigators hypothesize that fluid bolus given due to oliguria does not improve urine output in a majority of patients, especially among those with acute kidney injury. Another study hypothesis is that patients receiving fluid bolus will have higher levels of endothelial damage biomarkers. Intervention description: Intervention group -follow-up without intervention; No intervention to increase the urine output within 2 hours will be done. Standard group - Fluid bolus group: Patient will receive 500mL of balanced crystalloid intravenously over 30 minutes. In both groups, if severe hemodynamic instability occurs, a rescue bolus of 500mL over 30 minutes may be given according to the decision of the treating clinician. In both groups, all other ongoing infusions (nutrition and on-going clear fluids) will be held constant during the 2-hour period. Vasoactive medications, sedation, short-acting insulin, and other medications can be modified according the clinical need. No diuretics during the 2-hour study period are allowed. After two hours from randomization, treating clinician can modify the fluid and drug therapy according to the clinical needs of the patient. All administered fluids will be recorded 6 h from randomization. Except for the study intervention period of 2 hours, no attempt to control fluid therapy will be done. During the study period, all other aspects of critical care will follow the ICU's standard operating procedures and clinician's prescription.


Recruitment information / eligibility

Status Completed
Enrollment 130
Est. completion date December 10, 2020
Est. primary completion date December 10, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: - Age over 18 - Emergency admission to an ICU - Mean arterial pressure (MAP) >65 mmHg (with vasopressors if needed) and initial fluid resuscitation for shock/hypovolemia has been given - Oliguria (urine output less than 0.5mL/kg/h) for at least 2 consecutive hours Exclusion Criteria: - Marked fluctuations in hemodynamics within last 2 hours (cardiac arrhythmias, increase in norepinephrine need over 0.2ug/kg/min, need for initiation of inotrope/inodilator) - Administration of furosemide within last 6 hours - Chronic kidney disease (estimated pre-critical illness GFR < 60ml/min/1.73m2) - Renal replacement therapy - Among patients with acute kidney injury, urgent indications for commencing renal replacement therapy - Fluid overload (cumulative fluid accumulation exceeds 10% of baseline body weight) - Pulmonary edema (bilateral infiltrates in chest x-ray) - Active bleeding (need for transfusion, platelets, or fresh frozen plasma) - Suspected or known intra-abdominal hypertension (IAP >16mmHg) - Pregnant or lactating - Expected survival less than 24h - Obtaining informed consent is not possible/consent is denied

Study Design


Intervention

Other:
follow-up without intervention

fluid bolus


Locations

Country Name City State
Finland Helsinki University Hospital, Meilahti Helsinki Uusimaa
Finland Central Finland Central Hospital Jyväskylä

Sponsors (2)

Lead Sponsor Collaborator
Helsinki University Central Hospital Central Finland Central Hospital

Country where clinical trial is conducted

Finland, 

Outcome

Type Measure Description Time frame Safety issue
Other Number of patients receiving rescue boluses and the number of rescue boluses study intervention period (i.e. 2 hours)
Other Highest stage of acute kidney injury within 24 hours, 48 hours and during ICU stay (an average of 5 to 7 days or up to 30 days if patient is still in ICU)
Other Number of patients with one or several protocol violation(s) and number of those per patient study intervention period (i.e. 2 hours)
Other Number of patients with adverse events from randomization to next morning
Other Number of patients receiving renal replacement therapy during ICU stay(an average of 5 to 7 days or up to 30 days if patient is still in ICU)
Other change in mean arterial pressure from randomization to 2 hours post-randomization
Other change in heart rate from randomization to 2 hours post-randomization
Primary Change in individual mean cumulative urine output (mL/kg/h) Doubling of the urine output is defined as clinically meaningful response 2 hours after randomization compared to urine output 2 hours preceding randomization
Secondary The difference between groups in the change in individual urine output 2 hours after randomization compared to urine output 2 hours preceding randomization
Secondary Duration of consecutive oliguria (urine output <0.5 mL/kg) during ICU stay, i.e. as long as urine output stays below 0.5 mL/kg/h while the patient is in the ICU (an average of 5 to 7 days) or until renal replacement therapy is commenced
Secondary Cumulative fluid balance six hours from randomization
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Recruiting NCT05578196 - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections. N/A
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3